New hope for hard-to-treat cancers: targeted drug enters human testing
NCT ID NCT07567859
First seen May 07, 2026 · Last updated Jun 16, 2026 · Updated 9 times
Summary
This early-stage study tests a new drug called HS-10587 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 362 participants who have tried other treatments without success will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MTAP DELETION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.